Arcus Biosciences - About the company
Arcus Biosciences is a public company based in Hayward (United States), founded in 2015. It operates as a Developer of immune-focused cancer therapies targeting the ATP-adenosine pathway. Arcus Biosciences has raised $227M in funding from Google Ventures and Droia Ventures. The company has 3364 active competitors, including 1135 funded and 783 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of immune-focused cancer therapies targeting the ATP-adenosine pathway. The company is developing small molecules and antibodies targeting key proteins involved in the ATP-adenosine pathway CD73, CD39, and the A2A receptor. It is discovering agents that target key therapeutics mechanisms involved in activation of immunogenic cancer cell death, activation of dendritic cells, a reversal of active immune suppression, and direct stimulation of effector immune cells (such as T and NK cells).
- Website
- arcusbio.com
- Social
- Registered Address
- Hayward, California
Key Metrics
Founded Year
2015
Location
Hayward, United States
Stage
Public
Total Funding
$227M in 3 rounds
Latest Funding Round
Investors
Ranked
480th among 3364 active competitors
Annual Revenue
$100M - $500M as on Dec 31, 2025
Employee Count
631 as on Sep 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Arcus Biosciences
Arcus Biosciences is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Arcus Biosciences, Inc. CIN: 1724521 , United States, Active | Apr 29, 2015 | $100M - $500M (As on Dec 31, 2025) | 577 (As on Dec 31, 2023) | - |
ARCUS BIOSCIENCES CIN: 473898435 , United States, Active | Dec 31, 1999 | - | 628 (As on Dec 31, 2024) | - |
Arcus Biosciences's IPO details
Arcus Biosciences got listed on Mar 15, 2018.
Click here to take a look at Arcus Biosciences's IPO in detail
Sign up to download Arcus Biosciences' company profile
Arcus Biosciences's funding and investors
Arcus Biosciences has raised a total funding of $227M over 3 rounds. Its first funding round was on May 01, 2015. Its latest funding round was a Series C round on Nov 13, 2017 for $*****. 14 investors participated in its latest round. Arcus Biosciences has 21 institutional investors.
Here is the list of recent funding rounds of Arcus Biosciences:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 13, 2017 | 4578398 | Series C | 2361186 | 7556184 | 4732145 | 6327431 |
Aug 29, 2016 | 4675872 | Series B | 4329368 | 9595282 | 2074100 | |
May 01, 2015 | 6218766 | Series A | 6184455 | 4330813 | 1582263 |
Access funding benchmarks and valuations. Sign up today!View details of Arcus Biosciences's funding rounds and investors
Arcus Biosciences' founders and board of directors
Founder? Claim ProfileArcus Biosciences' employee count trend
Arcus Biosciences has 631 employees as of Sep 26. Here is Arcus Biosciences's employee count trend over the years:
Uncover Arcus Biosciences' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Arcus Biosciences's Competitors and alternates
Top competitors of Arcus Biosciences include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Arcus Biosciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
480th | Arcus Biosciences 2015, Hayward (United States), Public | Developer of immune-focused cancer therapies targeting the ATP-adenosine pathway | $227M | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Arcus Biosciences's competitors? Click here to see the top ones
Arcus Biosciences's Investments and acquisitions
Arcus Biosciences has made no investments or acquisitions yet.
Reports related to Arcus Biosciences
Here is the latest report on Arcus Biosciences's sector:
News related to Arcus Biosciences
Filter this listMedia has covered Arcus Biosciences for a total of 30 events in the last 1 year, 17 of them have been about company updates and 3 about partnerships.
•
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline UpdateBusiness Wire•Aug 06, 2026•Arcus Biosciences
•
Arcus Biosciences and AVEO Oncology Sign Clinical Supply Agreement for Casdatifan EvaluationBenzinga•Jul 23, 2026•Arcus Biosciences, AVEO Pharmaceuticals
•
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% RunThe Motley Fool•Jul 13, 2026•Arcus Biosciences
•
Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire•Jun 25, 2026•Arcus Biosciences
•
Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire•Jun 09, 2026•Arcus Biosciences
•
Is Arcus‑BMS Kidney Cancer Collaboration Altering The Investment Case For Arcus Biosciences (RCUS)?Simply Wall St•Jun 04, 2026•Arcus Biosciences
•
BioNTech and Bristol Myers Squibb Announce Encouraging Efficacy of Bispecific PD-L1xVEGF-A Immunomodulator Candidate Pumitamig inGlobeNewswire•May 30, 2026•Bristol-Myers Squibb, Arcus Biosciences
•
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline UpdateBusiness Wire•May 05, 2026•Arcus Biosciences
•
Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire•Apr 25, 2026•Arcus Biosciences
•
Gilead declines another Arcus option after Phase 3 TIGIT failEndpoints•Apr 20, 2026•Arcus Biosciences, Gilead
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Arcus Biosciences
Explore our recently published companies
- Bin Arbaid Holding (Official) - Qatar based, 1987 founded, Unfunded company
- ITALCOL S.A - Mexico based, 2002 founded, Unfunded company
- TeePee - Territoire Performance - United States based, 2009 founded, Unfunded company
- Boom Two - Columbus based, Unfunded company
- Retrostar Vintage Clothing - Melbourne based, Unfunded company
- Chris Jarvis - Unfunded company
